AR 6121
Alternative Names: AR-6121Latest Information Update: 16 Feb 2023
At a glance
- Originator Aerie Pharmaceuticals
- Developer Alcon
- Class Anti-inflammatories; Drug conjugates; Eye disorder therapies; Steroids
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Postoperative inflammation
Most Recent Events
- 21 Jun 2021 Preclinical trials in Postoperative inflammation in USA (Ophthalmic), prior to June 2021 (Aerie Pharmaceuticals website, June 2021)
- 21 Jun 2021 Aerie Pharmaceuticals announces intention to file an IND to the regulatory body for AR 6121 for Postoperative inflammation, in the second half of 2022 (Aerie Pharmaceuticals website, June 2021)
- 21 Jun 2021 Aerie Pharmaceuticals expects regulatory approval of AR 6121 for Postoperative inflammation